Search hospitals

>

New York

>

Stony Brook

Stony Brook University Medical Center

Claim this profile

Stony Brook, New York 11794

Global Leader in Cancer

Global Leader in Breast Cancer

Conducts research for Lung Cancer

Conducts research for Heart Failure

Conducts research for Ovarian Cancer

565 reported clinical trials

54 medical researchers

Photo of Stony Brook University Medical Center in Stony BrookPhoto of Stony Brook University Medical Center in Stony Brook

Summary

Stony Brook University Medical Center is a medical facility located in Stony Brook, New York. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Heart Failure, Ovarian Cancer and other specialties. Stony Brook University Medical Center is involved with conducting 565 clinical trials across 980 conditions. There are 54 research doctors associated with this hospital, such as Laura E. Hogan, David Fiorella, MD, Minsig Choi, and Amna Sher.

Area of expertise

1

Cancer

Global Leader

Stony Brook University Medical Center has run 59 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage I
p16 positive
2

Breast Cancer

Global Leader

Stony Brook University Medical Center has run 51 trials for Breast Cancer. Some of their research focus areas include:

ER positive
Stage IV
HER2 negative

Top PIs

Clinical Trials running at Stony Brook University Medical Center

Breast Cancer

Lung Cancer

Breast cancer

Prostate Cancer

Multiple Myeloma

Cancer

Testicular cancer

Pancreatic Cancer

Leukemia

Ovarian Carcinoma

Image of trial facility.

PF-07220060 + Letrozole

for Breast Cancer

The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (the spread of cancer to other places in the body) * who have not received any prior systemic anti-cancer treatment for advanced/metastatic disease. Approximately half of the participants will receive PF-07220060 plus letrozole while the other half of participants will receive the investigator's choice of treatment plus letrozole. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Radiation and HER2-Targeted Therapy

for Breast Cancer

This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.

Recruiting

2 awards

Phase 3

15 criteria

Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.

Recruiting

2 awards

Phase 3

40 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Stony Brook University Medical Center?

Where is Stony Brook University Medical Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does Stony Brook University Medical Center accept?

What awards or recognition has Stony Brook University Medical Center received?